A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)
Latest Information Update: 23 Jan 2023
At a glance
- Drugs Alvelestat (Primary)
- Indications COVID-19 respiratory infection
- Focus Adverse reactions
- Acronyms COSTA
- 03 Mar 2022 According to a Mereo Biopharma media release, update from the study will be discussed in a virtual R&D Day on 14th March 2022.
- 22 Dec 2021 Results presented in a University of Alabama at Birmingham Media Release.
- 16 Nov 2021 Status changed from active, no longer recruiting to completed.